The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 29, 2022

Filed:

Mar. 01, 2021
Applicant:

Exela Pharma Sciences, Llc, Lenoir, NC (US);

Inventors:

John Maloney, Salisbury, NC (US);

Aruna Koganti, Lenoir, NC (US);

Phanesh Koneru, Waxhaw, NC (US);

Assignee:

EXELA PHARMA SCIENCES, LLC, Lenoir, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4172 (2006.01); A61K 33/06 (2006.01); A61K 31/191 (2006.01); A61K 47/02 (2006.01); A61K 33/36 (2006.01); A61K 33/241 (2019.01); A61K 33/28 (2006.01); A61K 33/00 (2006.01); A61K 31/405 (2006.01); A61K 31/401 (2006.01); A61K 9/00 (2006.01); A23L 33/175 (2016.01); A23L 33/16 (2016.01); A61K 31/198 (2006.01); A61K 31/095 (2006.01); A61J 1/14 (2006.01);
U.S. Cl.
CPC ...
A61K 33/06 (2013.01); A23L 33/16 (2016.08); A23L 33/175 (2016.08); A61K 9/0029 (2013.01); A61K 31/095 (2013.01); A61K 31/191 (2013.01); A61K 31/198 (2013.01); A61K 31/401 (2013.01); A61K 31/405 (2013.01); A61K 31/4172 (2013.01); A61K 33/00 (2013.01); A61K 33/241 (2019.01); A61K 33/28 (2013.01); A61K 33/36 (2013.01); A61K 47/02 (2013.01); A23V 2002/00 (2013.01); A61J 1/1412 (2013.01);
Abstract

The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cysteine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace Othat is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.


Find Patent Forward Citations

Loading…